Since the discovery of thienamycin, carbapenems have been well known for exhibiting very potent antimicrobial activities against a broad spectrum of bacteria (1, 5) . All of the carbapenem derivatives including imipenem, however, have been found to undergo metabolism by a renal tubular brush border dipeptidase, dehydropeptidase-I (DHP-I) (4, 11) and to be relatively unstable in aqueous solution. These features result in low concentrations in urine, which is one of the major hindrances to the clinical application of these drugs. To overcome these defects, a compound which possesses potent broad-spectrum antimicrobial activity stable enough for clinical practice without coadministration of DHP-I inhibitor has been much desired. LJC 10,627; a new 1-,-methyl carbapenem antibiotic, has an extremely wide spectrum of in vitro antibacterial activity, including activity against most aerobic and anaerobic grampositive and gram-negative bacteria (9) . In this paper, we report a remarkable stability of LJC 10,627 against human and animal DHP-Is.
LJC 10,627 (1-p-methyl compound; Fig. 1 The test compound (at a final concentration of 100 ,uM) was added to the enzyme solution in 50 mM MOPS buffer (pH 7.0). The enzyme activity used was 2.6 U/ml. One unit of the enzyme was defined as the amount of enzyme which hydrolyzed 1 ,uM glycyldehydrophenylalanine per min at 30°C in 50 mM MOPS buffer (pH 7.0). Aliquots of the reaction mixture were collected at 0.25, 0.5, 1, 2, and 4 h after incubation and then mixed with 2 volumes of acetonitrile by vortexing. Chloroform was added to a final concentration of 50% (vol/vol) and mixed well. The remaining drug concentration in the supernatant fluid after centrifugation at 5,000 x g for 10 min was determined by high-pressure liquid chromatography (HPLC). The HPLC system consists of a Waters 600E, a Waters 712 WISP, and a Jasco 870 UV detector. The chromatographic conditions used are shown in Table 2 . After incubation at 300C for 2 h, the residual amount of LJC 10,627 decreased by only about 8% of the initial amount, while that of imipenem decreased by 79% after only 0.5 h (Fig. 2) . The datum points shown in the figure are the means of two independent experiments for each compound. The kinetic profile of the reactions of LJC 10,723 with the three enzymes differs from those of both LJC 10,627 and imipenem. It indicates that high stability against DHP-I is attributable not only to 1-,-methylation but also to the presence of a triazolium radical at the side chain of the second position. Further support for this notion may be provided by the fact that meropenem (SM-7338), a derivative of 1-p-methyl-carbapenem, is only four times more stable than imipenem for human renal DHP-I according to a comparison of the VmaxlKm ratios (8) . In comparison with the present result, meropenem seems to be more unstable against human renal DHP-I in spite of the presence of a 1-p-methyl base in its chemical structure.
It is well known that inactivation of carbapenems readily occurs because of metabolic degradation in vivo. This is one of the major obstacles against their successful introduction to the clinical field. Some advance in the stability of carbapenems has been brought about by formation of meropenem and panipenem (CS-533), which, compared with imipenem, are durable against the decomposing actions of DHP-I and/or f-lactamase (6, 7) without needing a DHP-I inhibitor. LJC 10,627 appears to have achieved further advances with respect to stability. This new compound deserves further studies and clinical trials to determine its role in modern chemotherapy.
